miltefosine has been researched along with arachidonic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdeen, S; Chapman, E; Chitre, S; Hoang, QQ; Johnson, SM; Park, Y; Ray, AM; Salim, N; Sivinski, J; Stevens, M; Washburn, A | 1 |
| Bäumer, W; Jennings, G; Rundfeldt, C; Wlaź, P | 1 |
2 other study(ies) available for miltefosine and arachidonic acid
| Article | Year |
|---|---|
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
Topics: Biological Products; Chaperonin 10; Chaperonin 60; Escherichia coli; Humans; Inhibitory Concentration 50; Protein Folding; Rafoxanide; Salicylanilides; Suramin | 2019 |
The putative lipid raft modulator miltefosine displays immunomodulatory action in T-cell dependent dermal inflammation models.
Topics: Administration, Oral; Administration, Topical; Animals; Anti-Inflammatory Agents; Arachidonic Acid; Disease Models, Animal; Ear; Female; Hypersensitivity; Immunologic Factors; Inflammation; Interleukins; Membrane Microdomains; Mice; Phosphorylcholine; Pruritus; Skin; T-Lymphocytes; Toluene 2,4-Diisocyanate | 2010 |